Erschienen in:

07.09.2024 | Colorectal Cancer

Differences in Prognosis and Recurrence Patterns Between Ulcerative Colitis-Associated Colorectal Cancer and Sporadic Colorectal Cancer: A Matched-Pair Analysis

verfasst von: Kei Kobayashi, MD, Kenichiro Toritani, MD, PhD, Hideaki Kimura, MD, PhD, Jun Kawashima, MD, Koki Goto, MD, PhD, Yusuke Suwa, MD, PhD, Mayumi Ozawa, MD, PhD, Asushi Ishibe, MD, PhD, Jun Watanabe, MD, PhD, Itaru Endo, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Clinicopathological differences exist between ulcerative colitis-associated colorectal cancer (UC-CRC) and sporadic colorectal cancer (S-CRC). However, differences in the prognosis remain controversial, and the reason for these differences remains unclear. We therefore assessed the differences between patients with UC-CRC and S-CRC.

Patients and Methods

This was a matched-pair analysis of the clinicopathological characteristics and prognosis of patients with UC-CRC and S-CRC who underwent colorectal resection between January 2000 and December 2021 at two institutions. Patients were matched according to age, sex, date of surgery, tumor location, and Union for International Cancer Control (UICC) stage.

Results

A total of 5992 patients underwent surgery for CRC at the two institutions, and 288 patients (48 with UC-CRC and 240 with S-CRC) were matched in this study. Patients with UC-CRC underwent more invasive surgery and had a longer operative time than those with S-CRC, but there was no marked difference in postoperative complications or perioperative mortality. Long-term outcomes showed a similar 5-year overall survival (OS) for UC-CRC and S-CRC (86.5% versus 88.8%, p = 0.742); however, in stage 3 patients, patients with UC-CRC had a poorer 5-year OS than those with S-CRC (51.4% versus 83.8%, p = 0.032). The first recurrence sites in stage 3 UC-CRC were peritoneal dissemination followed by the bones, while those in S-CRC were the liver and pulmonary system.

Conclusions

Despite no significant differences in surgical outcomes, patients with UC-CRC had a poorer prognosis than those with S-CRC at stage 3. The recurrence patterns in UC-CRC differed from those in S-CRC, suggesting a possible prognostic difference.

Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152(2):313–21. https://doi.org/10.1053/j.gastro.2016.10.020.CrossRefPubMed

Jess T, Horvath-Puho E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: A Danish population-based cohort study. Am J Gastroenterol. 2013;108(12):1869–76. https://doi.org/10.1038/ajg.2013.249.CrossRefPubMed

Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: A nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12(2):265–73. https://doi.org/10.1016/j.cgh.2013.03.034.CrossRefPubMed

Hrabe JE, Byrn JC, Button AM, Zamba GK, Kapadia MR, Mezhir JJ. A matched case-control study of IBD-associated colorectal cancer: IBD portends worse outcome. J Surg Oncol. 2014;109(2):117–21. https://doi.org/10.1002/jso.23465.CrossRefPubMed

Gearhart SL, Nathan H, Pawlik TM, Wick E, Efron J, Shore AD. Outcomes from IBD-associated and non-IBD-associated colorectal cancer: A Surveillance Epidemiology and End Results Medicare study. Dis Colon Rectum. 2012;55(3):270–7. https://doi.org/10.1097/DCR.0b013e318242620f.CrossRefPubMed

Ording AG, Horváth-Puhó E, Erichsen R, et al. Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn’s disease: a nationwide population-based cohort study. Inflamm Bowel Dis Mar-Apr. 2013;19(4):800–5. https://doi.org/10.1097/MIB.0b013e3182802af7.CrossRef

Renz BW, Thasler WE, Preissler G, et al. Clinical outcome of IBD-associated versus sporadic colorectal cancer: a matched-pair analysis. J Gastrointest Surg. 2013;17(5):981–90. https://doi.org/10.1007/s11605-013-2171-z.CrossRefPubMed

Noguchi T, Ishihara S, Uchino M, et al. Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn’s disease. J Gastroenterol. 2023;58(1):14–24. https://doi.org/10.1007/s00535-022-01927-y.CrossRefPubMed

Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis. 2011;17(3):802–8. https://doi.org/10.1002/ibd.21365.CrossRefPubMed

10.

Jensen AB, Larsen M, Gislum M, et al. Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish study. Am J Gastroenterol. 2006;101(6):1283–7. https://doi.org/10.1111/j.1572-0241.2006.00520.x.CrossRefPubMed

11.

Lin VA, Lohse R, Madsen MT, Fransgaard T, Remzi FH, Gögenur I. Long-term outcomes after colorectal surgery in patients with ulcerative colitis-associated colorectal cancer versus sporadic colorectal cancer. Ann Surg Oncol. 2022;29(4):2505–12. https://doi.org/10.1245/s10434-021-10759-8.CrossRefPubMed

12.

Leowardi C, Schneider ML, Hinz U, et al. Prognosis of ulcerative colitis-associated colorectal carcinoma compared to sporadic colorectal carcinoma: a matched pair analysis. Ann Surg Oncol. 2016;23(3):870–6. https://doi.org/10.1245/s10434-015-4915-3.CrossRefPubMed

13.

Han YD, Al Bandar MH, Dulskas A, et al. Prognosis of ulcerative colitis colorectal cancer vs. sporadic colorectal cancer: propensity score matching analysis. BMC Surg. 2017;17(1):28. https://doi.org/10.1186/s12893-017-0224-z.CrossRefPubMedPubMedCentral

14.

Shaukat A, Salfiti NI, Virnig DJ, et al. Is ulcerative colitis associated with survival among older persons with colorectal cancer in the US? A population-based case-control study. Dig Dis Sci. 2012;57(6):1647–51. https://doi.org/10.1007/s10620-011-1966-6.CrossRefPubMed

15.

Kuwabara H, Kimura H, Kunisaki R, et al. Postoperative complications, bowel function, and prognosis in restorative proctocolectomy for ulcerative colitis-a single-center observational study of 320 patients. Int J Colorectal Dis. 2022;37(3):563–72. https://doi.org/10.1007/s00384-021-04059-6.CrossRefPubMed

16.

Toritani K, Kimura H, Goto K, et al. Curable leakage in stapled IPAA has little effect on the long-term pouch function. Int J Colorectal Dis. 2023;38(1):43. https://doi.org/10.1007/s00384-023-04339-3.CrossRefPubMed

17.

Hashiguchi Y, Muro K, Saito Y, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42. https://doi.org/10.1007/s10147-019-01485-z.CrossRefPubMed

18.

Watanabe T, Muro K, Ajioka Y, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23(1):1–34. https://doi.org/10.1007/s10147-017-1101-6.CrossRefPubMed

19.

Watanabe T, Itabashi M, Shimada Y, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20(2):207–39. https://doi.org/10.1007/s10147-015-0801-z.CrossRefPubMedPubMedCentral

20.

Watanabe T, Itabashi M, Shimada Y, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2012;17(1):1–29. https://doi.org/10.1007/s10147-011-0315-2.CrossRefPubMed

21.

Abdalla EK. Resection of colorectal liver metastases. J Gastrointest Surg. 2011;15(3):416–9. https://doi.org/10.1007/s11605-011-1429-6.CrossRefPubMed

22.

Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15(3):938–46. https://doi.org/10.1200/jco.1997.15.3.938.CrossRefPubMed

23.

Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84(1):324–38. https://doi.org/10.1016/j.athoracsur.2007.02.093.CrossRefPubMed

24.

Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709–19. https://doi.org/10.1016/s1470-2045(16)30500-9.CrossRefPubMed

25.

Franko J. Therapeutic efficacy of systemic therapy for colorectal peritoneal carcinomatosis: surgeon’s perspective. Pleura Peritoneum. 2018;3(1):20180102. https://doi.org/10.1515/pp-2018-0102.CrossRefPubMedPubMedCentral

26.

Brentnall TA, Crispin DA, Bronner MP, et al. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res. 1996;56(6):1237–40.PubMed

27.

Watanabe T, Kobunai T, Toda E, et al. Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray. Clin Cancer Res. 2007;13(2 Pt 1):415–20. https://doi.org/10.1158/1078-0432.Ccr-06-0753.CrossRefPubMed

28.

Yaeger R, Shah MA, Miller VA, et al. Genomic alterations observed in colitis-associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology. 2016;151(2):278-287.e6. https://doi.org/10.1053/j.gastro.2016.04.001.CrossRefPubMed

29.

Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140(6):1807–16. https://doi.org/10.1053/j.gastro.2011.01.057.CrossRefPubMed

30.

Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–67. https://doi.org/10.1016/0092-8674(90)90186-i.CrossRefPubMed

31.

Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–32. https://doi.org/10.1056/nejm198809013190901.CrossRefPubMed

32.

Muto T, Nagawa H, Watanabe T, Masaki T, Sawada T. Colorectal carcinogenesis: historical review. Dis Colon Rectum. 1997;40(10 Suppl):S80–5. https://doi.org/10.1007/bf02062026.CrossRefPubMed

33.

Watanabe T, Ajioka Y, Mitsuyama K, et al. Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology. 2016;151(6):1122–30. https://doi.org/10.1053/j.gastro.2016.08.002.CrossRefPubMed

34.

Chambers WM, Warren BF, Jewell DP, Mortensen NJ. Cancer surveillance in ulcerative colitis. Br J Surg. 2005;92(8):928–36. https://doi.org/10.1002/bjs.5106.CrossRefPubMed

35.

Aiken T, Hu CY, Uppal A, et al. Peritoneal recurrence after resection for Stage I-III colorectal cancer: a population analysis. J Surg Oncol. 2023;127(4):678–87. https://doi.org/10.1002/jso.27175.CrossRefPubMed

36.

Kim SH, Shin SJ, Lee KY, et al. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. Ann Surg Oncol. 2013;20(11):3407–13. https://doi.org/10.1245/s10434-013-3169-1.CrossRefPubMed

37.

Huang JF, Shen J, Li X, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med. 2020;8(7):482. https://doi.org/10.21037/atm.2020.03.55.CrossRefPubMedPubMedCentral

38.

Riffel RM, Göbel A, Rachner TD. Bone metastases: from mechanisms to treatment. Semin Oncol Nurs. 2022;38(2):151277. https://doi.org/10.1016/j.soncn.2022.151277.CrossRefPubMed

39.

Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst. 1998;90(2):118–23. https://doi.org/10.1093/jnci/90.2.118.CrossRefPubMed

40.

Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 2005;328(3):679–87. https://doi.org/10.1016/j.bbrc.2004.11.070.CrossRefPubMed

41.

Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655–64. https://doi.org/10.1056/NEJMra030831.CrossRefPubMed

42.

Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–35. https://doi.org/10.1136/gut.48.4.526.CrossRefPubMedPubMedCentral

43.

Kishikawa J, Hata K, Kazama S, et al. Results of a 36-year surveillance program for ulcerative colitis-associated neoplasia in the Japanese population. Dig Endosc. 2018;30(2):236–44. https://doi.org/10.1111/den.12955.CrossRefPubMed

44.

Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130(4):1030–8. https://doi.org/10.1053/j.gastro.2005.12.035.CrossRefPubMed

45.

Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. 2020;395(10218):123–31. https://doi.org/10.1016/s0140-6736(19)32545-0.CrossRefPubMed

46.

Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413. https://doi.org/10.14309/ajg.0000000000000152.CrossRefPubMed

47.

Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–70. https://doi.org/10.1093/ecco-jcc/jjx008.CrossRefPubMed

48.

Hata K, Anzai H, Ikeuchi H, et al. Surveillance colonoscopy for ulcerative colitis-associated colorectal cancer offers better overall survival in real-world surgically resected cases. Am J Gastroenterol. 2019;114(3):483–9. https://doi.org/10.14309/ajg.0000000000000117.CrossRefPubMed

Titel: Differences in Prognosis and Recurrence Patterns Between Ulcerative Colitis-Associated Colorectal Cancer and Sporadic Colorectal Cancer: A Matched-Pair Analysis
verfasst von: Kei Kobayashi, MD
Kenichiro Toritani, MD, PhD
Hideaki Kimura, MD, PhD
Jun Kawashima, MD
Koki Goto, MD, PhD
Yusuke Suwa, MD, PhD
Mayumi Ozawa, MD, PhD
Asushi Ishibe, MD, PhD
Jun Watanabe, MD, PhD
Itaru Endo, MD, PhD
Publikationsdatum: 07.09.2024
Verlag: Springer International Publishing
Erschienen in: Annals of Surgical Oncology / Ausgabe 12/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-16158-z

Single Port Robotic Liver Resection: Metastasectomy for Recurrent Fibrolamellar Hepatocellular Carcinoma

Hepatobiliary Tumors

ASO Author Reflections: Ante Situm Hepatectomy—When Transplant and Resection Techniques Are Combined for Extreme Liver Surgery

ASO Author Reflections

ASO Visual Abstract: Incidence of High-Risk and Malignant Pathological Findings in Transgender and Gender-Diverse Individuals Undergoing Gender-Affirming Mastectomy

ASO Visual Abstract

Racial–Ethnic Comparison of Treatment for Papillary Thyroid Cancer in the Military Health System

Head and Neck Oncology

ASO Author Reflections: Young Adults and Racial Minorities May Be at High Risk for Financial Toxicity After Breast Cancer Treatment

ASO Author Reflections

Dynamic Anthropometrics in Pancreatic Cancer: Associations Between Body Composition Changes During Neoadjuvant Therapy and Survival Outcomes After Resection

Pancreatic Tumors

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

29.04.2025
DGK-Jahrestagung 2025
Kongressbericht

Bisher wird für den interventionellen Mitralklappenersatz standardmäßig der transapikale Zugangsweg gewählt. In einer Registeranalyse hat dieser in puncto Sicherheit allerdings den Kürzeren gezogen.

Lohnt sich die Karotis-Revaskularisation?

25.04.2025
Karotisstenose
Nachrichten

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

25.04.2025
Zerebrale Metastasen
Nachrichten

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Appendektomie erhält Remission bei Colitis ulcerosa

24.04.2025
Colitis ulcerosa
Nachrichten

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Differences in Prognosis and Recurrence Patterns Between Ulcerative Colitis-Associated Colorectal Cancer and Sporadic Colorectal Cancer: A Matched-Pair Analysis

Abstract

Background

Patients and Methods

Results

Conclusions

Weitere Artikel der Ausgabe 12/2024

Single Port Robotic Liver Resection: Metastasectomy for Recurrent Fibrolamellar Hepatocellular Carcinoma

ASO Author Reflections: Ante Situm Hepatectomy—When Transplant and Resection Techniques Are Combined for Extreme Liver Surgery

ASO Visual Abstract: Incidence of High-Risk and Malignant Pathological Findings in Transgender and Gender-Diverse Individuals Undergoing Gender-Affirming Mastectomy

Racial–Ethnic Comparison of Treatment for Papillary Thyroid Cancer in the Military Health System

ASO Author Reflections: Young Adults and Racial Minorities May Be at High Risk for Financial Toxicity After Breast Cancer Treatment

Dynamic Anthropometrics in Pancreatic Cancer: Associations Between Body Composition Changes During Neoadjuvant Therapy and Survival Outcomes After Resection

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

Lohnt sich die Karotis-Revaskularisation?

Höhere Dosis von Dexamethason senkt Überlebenschancen

Appendektomie erhält Remission bei Colitis ulcerosa

Update Chirurgie

Springer Medizin

Abstract

Background

Patients and Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten